INDIVA (TSXV:NDVA) was recently profiled in an article on WeedReader regarding the company’s plans to take over the cannabis edibles and derivative product market.

The article outlines the company’s goals and objectives. By focusing on client care and delivering a highly standardized product, INDIVA works hard to be financially and environmentally sustainable. Moreover, the company is able to achieve their goals by making sure they retain control over all their ventures. “This means owning their production and processing facilities in London, Ontario, while gaining exclusive rights through their partnership agreements. “


The article further talks about the companies two most recent acquisitions and partnership ventures with companies in the cannabis edibles market. Despite the government’s reluctance to legalize cannabis edibles at the same time as legalizing recreational cannabis, INDIVA COO believes that “There are a lot of patients and people who do not wish to smoke cannabis but still want access to its benefits. Cannabis edibles are perfect for this and the market is deficient so far. While cannabis flowers are the backbone of our operations, we anticipate producing and selling cannabis edibles to separate us from the competition. Our partnerships with Bhang and DeepCell are indicative of this and an important aspect of our business plan.”

To read the full article, click here.

Click here to connect with INDIVA (TSXV:NDVA) to receive an Investors Presentation.

Source: weedreader.com

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less